They announce that they managed to extend the Maxigenic licence in South America, but nowhere do they mention where this drug is manufactured.
So far I have seen no indication that they (AFT) manufacture their stuff anywhere else than in India, which would mean that their partner "Pharma Bavaria" (which by the way seems to run a very small and sad looking head office in an insignificant Bavarian town with entry through the backyard) would tell their customers porkies if they really sells AFT product.
Well, at least its not just a post box ;
Have another look ...
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
Like many other shares I use to hold, I haven't been following AFT for a while and still haven't been able to jump back in (interestingly, I did note the share price is still 20 ish cents lower than when I sold out in early February).
Having been a holder of AFT since IPO in December 2015 (and topping up in the following years) I am certainly keen to get back into AFT as holistically speaking still believe it is a $5+ share right now.
AFT's interim results out Thursday next week will help determine how much more than $5 should be an appropriate price target.
Last edited by trader_jackson; 14-11-2021 at 01:47 PM.
Ok BP did some research
You’re correct on the release not saying where Maxigesic IV is made
Did some research as you had me thinking and didn’t want to accuse 2 companies of misleading us without some evidence
Medsafe databases list manufacturers http://www.medsafe.govt.nz/Regulator...l.asp?ID=19770
Made in Italy as opposed to India
Ok BP did some research
You’re correct on the release not saying where Maxigesic IV is made
Did some research as you had me thinking and didn’t want to accuse 2 companies of misleading us without some evidence
Medsafe databases list manufacturers http://www.medsafe.govt.nz/Regulator...l.asp?ID=19770
Made in Italy as opposed to India
Good research and interesting find ... I didn't realise that this information is readily available.
However - while the Medsafe data sheet says that the final dose was "manufactured" in Italy, it says as well that its main (or actually sole) components are manufactured in India (the Ibuprofen) and in Gebze, Turkey which is not in Europe, but part of Asia (the Paracetamol).
Hmm ... just to remember -
the Pharma Bavaria website says "Exclusively manufactured in Europe"
So - if I assemble a cell phone in NZ by plugging the battery (manufactured in Indonesia) into the body (manufactured in Malaysia), does this mean I am allowed to sell this cellphone as "Exclusively manufactured in New Zealand"?
I don't think so ...
Anyway - great discussion - I learned something new.
Last edited by BlackPeter; 16-11-2021 at 09:27 AM.
----
"Prediction is very difficult, especially about the future" (Niels Bohr)
Well I thought the results were pretty good... NPAT probably about $16m this year (a very rough estimate by me, probably a bit conservative).
If it is about 16m NPAT for FY22, this will mark the 3rd year in a row AFT has roughly doubled NPAT [$3.1m in 2020, $7.9m in 2021, $16m in 2022?]
Can they double it again in FY23? Quite possibly - and if so, the FY23 PE is just 15 (with a current market cap of $497m)... FY22 PE is 31x, an arguably conservative multiple in this market for a company growing very nicely indeed.
Originally Posted by Klaus129
Reply With Quote
;
Bookmarks